Development and Validation of a Nomogram for the Estimation of Response to Platinum-Based Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer

References

• Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X30638582
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu L, Tong R, et al. PD-1/PD-L1 inhibitors in cervical cancer. Front Pharmacol. 2019;10:65. doi:10.3389/fphar.2019.0006530774597
   PubMed Web of Science ®Google Scholar
• Lapresa M, Parma G, Portuesi R, et al. Neoadjuvant chemotherapy in cervical cancer: an update. Expert Rev Anticancer Ther. 2015;15(10):1171–1181. doi:10.1586/14737140.2015.107977726402247
   PubMed Web of Science ®Google Scholar
• Li R, Lu S-T, Si J-G, et al. Prognostic value of responsiveness of neoadjuvant chemotherapy before surgery for patients with stage IB(2)/IIA(2) cervical cancer. Gynecol Oncol. 2013;128(3):524–529. doi:10.1016/j.ygyno.2012.11.00623146686
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research. Anticancer Res. 2020;40(9):4819–4828. doi:10.21873/anticanres.1448532878770
   PubMed Web of Science ®Google Scholar
• Moore DH. Neoadjuvant chemotherapy for cervical cancer. Expert Opin Pharmacother. 2003;4(6):859–867. doi:10.1517/14656566.4.6.85912783583
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu L, Cai J, et al. The efficacy and response predictors of platinum-based neoadjuvant chemotherapy in locally advanced cervical cancer. Cancer Manag Res. 2020;12:10469–10477. doi:10.2147/CMAR.S27025833122946
   PubMed Web of Science ®Google Scholar
• Nishino M. Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond. Am Soc Clin Oncol Educ Book. 2018;38(38):1019–1029. doi:10.1200/EDBK_20144130231378
   PubMedGoogle Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–1931. doi:10.1093/eurheartj/ehu20724898551
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8(1):53. doi:10.1186/1472-6947-8-5319036144
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–574. doi:10.1177/0272989X0629536117099194
   PubMed Web of Science ®Google Scholar
• Benson R, Pathy S, Kumar L, et al. Locally advanced cervical cancer – neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: a Phase II study. J Cancer Res Ther. 2019;15(6):1359–1364. doi:10.4103/jcrt.JCRT_39_1831898673
   PubMed Web of Science ®Google Scholar
• Ye Q, Yuan H-X, Chen H-L. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis. J Cancer Res Clin Oncol. 2013;139(11):1887–1898. doi:10.1007/s00432-013-1509-y24022086
   PubMed Web of Science ®Google Scholar
• Fuso L, Mazzola S, Marocco F, et al. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report. Gynecol Oncol. 2005;99(Suppl 3):S187–91. doi:10.1016/j.ygyno.2005.07.07916185756
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Zola P, et al. Pretreatment platelet and hemoglobin levels are neither predictive nor prognostic variables for patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: a retrospective Italian study. Int J Gynecol Cancer. 2010;20(8):1399–1404. doi:10.1111/IGC.0b013e3181f1574e21051984
   PubMed Web of Science ®Google Scholar
• Park J-S, Jeon EK, Chun SH, et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol. 2011;120(2):275–279. doi:10.1016/j.ygyno.2010.10.03421093896
   PubMed Web of Science ®Google Scholar
• Shariat SF, Capitanio U, Jeldres C, et al. Can nomograms be superior to other prediction tools? BJU Int. 2009;103(4):492–5; discussion 495–7. doi:10.1111/j.1464-410X.2008.08073.x
   Web of Science ®Google Scholar
• Kumar R, Geuna E, Michalarea V, et al. The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. Br J Cancer. 2015;112(7):1157–1165. doi:10.1038/bjc.2015.6725719834
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–163. doi:10.2217/fon.09.13620021215
   PubMed Web of Science ®Google Scholar
• Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol. 2007;19(2):203–208. doi:10.1016/j.coi.2007.02.00117292599
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GAP, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283–287. doi:10.1023/B:AGEN.0000029415.62384.ba15166496
   PubMedGoogle Scholar
• Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–1081. doi:10.1093/carcin/bgp12719468060
   PubMed Web of Science ®Google Scholar
• Lin EY, Li J-F, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66(23):11238–11246. doi:10.1158/0008-5472.CAN-06-127817114237
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim SH, Han J-Y, et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol. 2012;138(12):2009–2016. doi:10.1007/s00432-012-1281-422772951
   PubMed Web of Science ®Google Scholar
• Egan K, Crowley D, Smyth P, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011;6(10):e26125. doi:10.1371/journal.pone.002612522022533
   PubMed Web of Science ®Google Scholar
• Liu F, Zhou S, Tan L, et al. A retrospective cohort study on pretreated neutrophil-to-lymphocyte ratio and prognosis of small cell lung cancer: evidence of effect modification by chemotherapy regimen. Cancer Manag Res. 2020;12:10341–10352. doi:10.2147/CMAR.S26386333116889
   PubMed Web of Science ®Google Scholar
• Lee SM, Russell A, Hellawell G. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma. Korean J Urol. 2015;56(11):749–755. doi:10.4111/kju.2015.56.11.74926568792
   PubMedGoogle Scholar
• Yoneoka G, Bozhilov K, Wong LL. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma. Hepatoma Res. 2020;6:6. doi:10.20517/2394-5079.2020.57
   Google Scholar
• Bowen RC, Little NAB, Harmer JR, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(19):32171–32189. doi:10.18632/oncotarget.1629128418870
   PubMedGoogle Scholar
• Yang C, Wen H-B, Zhao Y-H, et al. Systemic inflammatory indicators as prognosticators in glioblastoma patients: a comprehensive meta-analysis. Front Neurol. 2020;11:580101. doi:10.3389/fneur.2020.58010133117267
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhou S, Liu Y, et al. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer. 2018;18(1):443. doi:10.1186/s12885-018-4318-529669528
   PubMed Web of Science ®Google Scholar
• Ethier J-L, Desautels D, Templeton A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. doi:10.1186/s13058-016-0794-128057046
   PubMed Web of Science ®Google Scholar